Drugs / pING-hHER3FL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03832855 | Jul 2020 → Mar 2026 overdue | — | Herbert Lyerly | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pING-hHER3FL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03832855 ↗ |
| Modality | Vaccine | “Plasmid vaccine containing HER3” NCT03832855 ↗ |
| Route | Intramuscular | “Patients enrolled in the study will receive pING-hHER3FL by intramuscular injection (IM)” NCT03832855 ↗ |